Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745014 | 0.88 | GABRA5 (0.61) | MAOBGABRA5ALOX5CYP3A4MAOA | |
| SCHEMBL2176479 | 0.88 | MAOB (0.58) | MAOBGABRA5ALOX5CYP3A4BCHE | |
| SCHEMBL30825708 | 0.87 | MAOB (0.60) | MAOBGABRA5PDGFRBPDGFRABCHE | |
| SCHEMBL2175219 | 0.86 | GABRA5 (0.60) | MAOBGABRA5ALOX5CYP3A4MAOA | |
| SCHEMBL16782973 | 0.85 | GABRA5 (0.56) | MAOBGABRA5ALOX5CYP3A4MAOA | |
| SCHEMBL27032783 | 0.84 | MAOB (0.61) | MAOBALOX5CYP3A4PDGFRBPDGFRA | |
| SCHEMBL24998828 | 0.80 | GABRA5 (0.48) | MAOBGABRA5ALOX5CYP3A4MAOA | |
| SCHEMBL9005108 | 0.80 | GABRA5 (0.48) | MAOBGABRA5ALOX5CYP3A4MAOA | |
| SCHEMBL1563949 | 0.79 | MAOB (0.54) | MAOBGABRA5ALOX5CYP3A4MAOA | |
| SCHEMBL15779670 | 0.79 | MAOB (0.59) | MAOBALOX5CYP3A4MAOABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368081-B | Andrographolide modified compound | 黑龙江珍宝岛药业股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-106800551-B | Andrographolide modified compound | 黑龙江珍宝岛药业股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | MEDSHINE DISCOVERY INC. (CN) | 2018-12-06 | — | — | US | disclosed |
| EP-3381912-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. (CN) | 2018-10-03 | — | — | EP | disclosed |
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| CN-102341386-A | Pyridine derivative | DAIICHI SANKYO CO LTD | 2012-02-01 | — | — | CN | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MAOB 1020/4885GABRA5 3990/4885ALOX5 760/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | MAOB 2671/4885GABRA5 1224/4885ALOX5 953/4885 |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | MAOB 2757/4885GABRA5 1142/4885ALOX5 1646/4885 |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | MAOB 2757/4885GABRA5 1142/4885ALOX5 1646/4885 |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | CYP11B2, CYP11B1, DUSP23 | MAOB 2671/4885GABRA5 1224/4885ALOX5 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.